FDA Approves New AndroGel Formulation

Share this article:

The FDA has approved Abbott's AndroGel 1.62%, a testosterone gel that restores levels of the hormone in hypogonadal men with half the volume of gel at the starting dose than delivered in AndroGel 1%.

The newly approved formulation contains 40.5 mg of testosterone in two pump presses, compared with the 1% gel's 50 mg in four pump presses.

With different dosage and administration instructions, the two gels are not interchangeable.

Share this article:
You must be a registered member of RUN to post a comment.

More in Hypogonadism

Low Testosterone Raises Atherosclerosis Risk in Diabetics

Low Testosterone Raises Atherosclerosis Risk in Diabetics

Low testosterone may increase cardiovascular (CV) risk in middle-aged men with type 2 diabetes.

Testosterone Therapy Does Not Raise Heart Attack Risk

Testosterone Therapy Does Not Raise Heart Attack Risk

Testosterone therapy for men who produce little to no hormones does not increase heart attack risk.

FDA Panel: Limit Testosterone Drug Use

FDA Panel: Limit Testosterone Drug Use

Joint committee also calls for drug makers to run heart-risk tests on popular 'Low T' products.